Seikagaku commenced Taiwan launch of HyLink®, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis, through TCM Biotech International.
The main ingredient of HyLink is a cross-linked hyaluronate hydrogel made using Seikagaku’s crosslinking technology. Since the highly viscoelastic hyaluronate hydrogel remains in the knee joint cavity for a long period of time, HyLink is expected to illicit a long-lasting improvement of symptoms by an administration of only 3 mL.
TCM is a pharmaceutical company with a nationwide sales network in Taiwan that has strengths in the fields of orthopedics and rehabilitation. In Taiwan, TCM exclusively distributes ARTZDispo® and Artzfors®, intra-articular multiple-injection viscosupplements manufactured by Seikagaku to treat knee osteoarthritis and rotator cuff lesions without complete tears.